ArticleFrontiers in pharmacology2017
Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety.Translational psychiatry · 2022Trial
- First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.British journal of clinical pharmacology · 2020Trial
- Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.Nature reviews. Endocrinology · 2026Review
- Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia.Pharmacology research & perspectives · 2026Article
- Identification of a novel perifornical-hypothalamic-area-projecting serotonergic system that inhibits innate panic and conditioned fear responses.Translational psychiatry · 2024Article
- A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders.Neuroscience applied · 2024Article
- The role of the orexin system in the neurobiology of anxiety disorders: Potential for a novel treatment target.Neuroscience applied · 2024Review
- Anxiolytic-like effects of the dual orexin receptor antagonist daridorexant in rats.Neuroscience applied · 2024Article
- Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone.Brain sciences · 2022Review
- Orexin Signaling: A Complex, Multifaceted Process.Frontiers in cellular neuroscience · 2022Review
- Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.Journal of medicinal chemistry · 2021Article
- Effect of Estrous Cycle on Behavior of Females in Rodent Tests of Anxiety.Frontiers in psychiatry · 2021Review
- The Paraventricular Nucleus of the Thalamus as an Integrating and Relay Node in the Brain Anxiety Network.Frontiers in behavioral neuroscience · 2021Review
- Experimental Drugs for Panic Disorder: An Updated Systematic Review.Journal of experimental pharmacology · 2021Review
- Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.Frontiers of neurology and neuroscience · 2021Review
- Hypocretin (Orexin) Replacement Therapies.Medicine in drug discovery · 2020Article
- Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.ACS medicinal chemistry letters · 2020Article
- Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.Neuroscience bulletin · 2020Review
- The contribution of orexins to sex differences in the stress response.Brain research · 2020Review
- Therapeutics development for addiction: Orexin-1 receptor antagonists.Brain research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Orexin neurons originating in the perifornical and lateral hypothalamic area are highly reactive to anxiogenic stimuli and have strong projections to anxiety and panic-associated circuitry. Recent studies support a role for the orexin system and in particular the orexin 1 receptor (OX1R) in coordinating an integrative stress response. However, no selective OX1R antagonist has been systematically tested in two preclinical models of using panicogenic stimuli that induce panic attack in the majority of people with panic disorder, namely an acute hypercapnia-panic provocation model and a model involving chronic inhibition of GABA synthesis in the perifornical hypothalamic area followed by intravenous sodium lactate infusion. Here we report on a novel brain penetrant, selective and high affinity OX1R antagonist JNJ-54717793 (1S,2R,4R)-7-([(3-fluoro-2-pyrimidin-2-ylphenyl)carbonyl]-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.